Bromocriptin

Bromocriptine

HCID 31101

Notizen Reaktionen

Daten werden ergänzt – meist innerhalb einer Minute fertig

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

CAS: 25614-03-3
Standard-SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
InChIKey: OZVBMTJYIDMWIL-AYFBDAFISA-N
Summenformel: C32H40BrN5O5
Durchschnittliche Molmasse: 654,606 g/mol
Monoisotopische Masse: 653,22128148

Namen und Bezeichner

Bevorzugter Name: Bromocriptine
IUPAC: 2-Bromo-12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman
Lokaler Name: Bromocriptin
Englischer Name: Bromocriptine
Summenformel: C32H40BrN5O5
Molmasse: 654.59

Namen und Synonyme

ParlodelbromocryptinebromoergocryptineBROMOCRITINE2-bromo-ergocryptinKriptonSAN 15-754bromocriptin,6’,18-trioneBROMOCRIPTINE

Datenbank-Bezeichner

CAS: 25614-03-3
PubChem CID: 31101
DTXSID: DTXSID1022687
ChEMBL: CHEMBL311816、CHEMBL493
ChEBI: CHEBI:3181
UNII: 3A64E3G5ZO
EC Number: 247-128-5
Nikkaji: J16.988I

Eigenschaften

Physikochemische Eigenschaften

Schmelzpunkt: 215 · 215-218° (dec)
Siedepunkt: 891.3 · 891.3±65.0 °C(Predicted)
Dichte: 1.2734 · 1.2734 (rough estimate)
Brechungsindex: 1.64 · 1.6400 (estimate)
pka: 4.9 · pKa 4.90±0.05(80% MCS t = RT) (Uncertain)
Wasserlöslichkeit: 2.07 mg/L · 2.07mg/L(temperature not stated)
InChIKey: OZVBMTJYIDMWIL-CCCBMRMVNA-N
SMILES: N12[C@@H](CC(C)C)C(N3CCC[C@@]3([H])[C@]1(O)O[C@@](C(C)C)(NC(=O)[C@H]1CN([C@]3([H])CC4=C(NC5C=CC=C(C4=5)C3=C1)Br)C)C2=O)=O |&1:1,11,13,16,23,26,r|
CAS Datenbank: 25614 · 25614-03-3(CAS DataBase Reference)

Sicherheit und Regulatorisches

Sicherheitsdaten

Toxizität: An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.

Chemie und Industrie

Anwendungen

VerwendenBromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and postencephalic Parkinsonism.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Imine Brombernsteinsure 12'-Hydroxy-5'α-isobutyl-2'-isopropylergotaman-3',6',18-trion N-Bromsuccinimid

Anbieter49 Anbieter

杭州品高化工有限公司0571-87658025 · [email protected]

中梦研（湖北）科技有限公司0717-6300888 18062399888 · [email protected]

Dayang Chem (Hangzhou) Co.,Ltd.+86-0571-88938639 17705817739 · [email protected]

Hebei Yanxi Chemical Co., Ltd.+86-17531190177 · [email protected]

LGM Pharma1-(800)-881-8210 · [email protected]

Ergänzende Hinweise

DefinitionAn semisynthetic ergotamine alkaloid derivative and powerful dopamine D2 agonist. It inhibits prolactin secretion and release from the pituitary and retards tumor growth.